Loading…
Clinical-stage biopharmaceutical company developing gedatolisib and other targeted therapies for breast cancer and solid tumors.
Clinical-stage biopharmaceutical company developing gedatolisib and other targeted therapies for breast cancer and solid tumors.
Has no approved product, so it is paid for by money raised from investors rather than by sales. Nearly everything hangs on the lead drug, gedatolisib, an intravenous drug that blocks two linked cell-growth signals, which still has to clear regulators. The CELsignia test is a side platform for selecting patients.
Moat: narrow (IP / patents). Patent-protected lead drug candidate gedatolisib in late-stage trials for HR+/HER2- breast cancer.
Headquarters: Minneapolis, Minnesota · Founded: 2007 · Employees: 155
Size Celcuity (CELC) is a United States Health Care company (Medical Specialties) with a market value of $3.27B, the 1489th largest of 3,117 United States companies the cockpit tracks. Shares closed at $66.79 on 6 Nov 2026.
Performance Over six months the shares fell 49.0%, against +6.2% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Credit Celcuity has 1 bond outstanding ($575M).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$196,000 | -$167,000 | -$129,947 | -$142,772 | -$210,918 |
| EBITDA | -$208M | -$172M | -$113M | -$66.1M | -$39.2M |
| Net income | -$226M | -$177M | -$112M | -$63.8M | -$40.4M |
| Free cash flow | -$192M | -$154M | -$83.7M | -$53.9M | -$36.2M |
| Capital expenditure | $571,000 | $249,000 | $249,878 | $97,644 | $158,768 |
| Total debt | $754M | $322M | $98.0M | $37.4M | $35.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Celcuity CELC | $3.27B | -49% | n/a | n/a | n/a | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Relay Therapeutics RLAY | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CELC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.6% | +7.3% | 10th lowest of 21 |
| 6-month return | -49.0% | +6.2% | lowest of 21 |
| Distance from 52-week high | -55.8% | -30.9% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 1.1× | 6.8% | +8.9% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 4.9× | 23.2% | -16.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 2.4× | 3.5% | +8.0% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 5.1× | -0.3% | +7.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | 6.7× | 46.5% | -0.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 4.3× | 9.6% | -4.2% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 3.6× | 12.6% | +11.1% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 5.2× | 35.6% | +88.2% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 1.7× | 13.7% | +10.8% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 7.4× | n/a | n/a |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 9.9× | 48.8% | +14.9% |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 4.9× | 55.7% | +20.9% |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 3.8× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 22.0× | -7.7% | -7.4% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 4.8× | -1.2% | +8.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 3.2× | 11.7% | +11.0% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 2.8× | 10.6% | +12.1% |
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 5.0× | n/a | n/a |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | 3,189.4× | n/a | n/a |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 1.6× | 6.8% | +7.1% |
Celcuity has 1 bond outstanding with $575M face value.